Aurealis Therapeutics is pleased to announce our sponsorship of the newly established EWMA Diabetic Foot Committee, an initiative launched by the European Wound Management Association (EWMA) in 2023. This committee is dedicated to improving the management and care of diabetic foot ulcers (DFUs) across Europe by implementing an International Working Group on the Diabetic Foot (IWGDF) guidelines and promoting increased research in this relevant area.
One key initiative supported by the committee is the Diabetic Foot Valley (DFV) concept, which originated in Tuscany, Italy, under the leadership of Professor Alberto Piaggesi. This model focuses on improving patient outcomes by creating communities of healthcare units that follow a shared, standardized approach to DFU management. It has already demonstrated considerable success in reducing disparities in care, increasing research involvement, and improving patient outcomes.
At Aurealis, our mission aligns closely with the goals of the EWMA Diabetic Foot Committee. AUP-16, our 4-in-1 bacterial cell and gene therapy, is currently ongoing a Phase 2 clinical trial for the treatment of diabetic foot ulcers. We are proud to contribute to the advancement of DFU care by supporting this key committee, which not only drives the adoption of guidelines but also facilitates collaboration among healthcare professionals, researchers, and industry leaders.
The EWMA conferences are important events for Aurealis Therapeutics, where we regularly engage with global experts to share insights about our current operations, connect with thought leaders, and discuss our latest clinical progress. Our continued presence in their events and current sponsorship highlight our commitment to advancing therapies for unmet medical needs, particularly for patients suffering from chronic wounds like DFUs.
We look forward to sharing our expertise and collaborating with industry peers at the upcoming EWMA events, the next being held in Barcelona on 26-28 March 2025.
About Aurealis Therapeutics
Aurealis Therapeutics AG is a Swiss-Finnish clinical-stage company developing scalable and low COGS multi-target cell and gene therapies allowing to modulate tissue microenvironment and tackle complex multi-factorial diseases such as chronic wounds, cancers, and inflammation. Aurealis modular gene therapy platform consists of non-pathogenic food-grade lactic acid bacterium Lactococcus Cremoris, genetically engineered to produce and release multiple human therapeutic proteins in the body: cytokines, chemokines, growth factors, antibody fragments. These living bacterium act as millions of nanoscale bioreactors at the site of the disease, allowing multi-targeting as one product, to treat multifactorial diseases. Aurealis pipeline includes Chronic Wounds (AUP-16, ongoing Phase 2), Oncology (AUP-55, pre-clinical stage), Inflammation (AUP-60, discovery stage).
For more information:
Laurent Décory, COO
Email: laurent@aurealistherapeutics.com
